Usana Health Sciences INC

USANA Health Sciences announced a second-quarter net loss of $21.4 million and reduced its fiscal year 2026 guidance, citing underperformance in its ventures businesses.

USANA Health Sciences held its Annual Meeting of Shareholders on May 20, 2026, with strong participation and key votes on board directors, auditor ratification, and executive compensation.

USANA Health Sciences announced its first quarter 2026 financial results, showing flat net sales and a decrease in net earnings, while reiterating its full-year guidance.

USANA Health Sciences, Inc. has disclosed the compensation packages for its reappointed CEO, Kevin Guest, and the transition agreement for former CEO Jim Brown.

USANA Health Sciences announced preliminary fiscal year 2025 net sales of $925 million, surpassing its guidance, and issued an initial fiscal year 2026 net sales outlook of $925 million to $1.0 billion, driven by growth in Hiya and Rise Wellness despite a projected decline in its core nutritional business.

USANA Health Sciences announced a leadership transition with Kevin Guest returning as Chief Executive Officer, succeeding Jim Brown, to accelerate growth and enhance shareholder value.

USANA Health Sciences reported a 0.3% increase in net sales to $250.2 million for Q1 2026, but net earnings attributable to USANA decreased by 20.1% to $7.5 million, impacted by lower operating margins and a higher tax rate.

USANA Health Sciences reported a net loss of $6.5 million in Q3 2025, primarily due to a significantly higher effective tax rate and a decline in its core direct selling segment, despite revenue growth from the Hiya acquisition.

USANA Health Sciences reports a 7.4% drop in Q2 net earnings and a 3.7% decrease in diluted EPS, despite a 10.8% revenue increase driven by the Hiya acquisition.

USANA Health Sciences' Q1 2025 results show a net sales increase driven by the Hiya acquisition, but a decrease in net earnings due to amortization costs and currency headwinds.

USANA Health Sciences experienced a decrease in both sales and earnings for the third quarter of 2024, primarily due to a challenging economic environment impacting customer acquisition and spending.

USANA Health Sciences experienced a decrease in both sales and earnings for the second quarter of 2024, primarily due to a decline in active customers and average customer spend.

USANA Health Sciences, Inc. reported a significant 74.4% decrease in net earnings for fiscal year 2025, despite an 8.3% increase in net sales driven by the Hiya acquisition, as its core nutritional business experienced a 14.8% decline in active customers.

USANA Health Sciences' 2024 results reveal a decrease in net sales and earnings, impacted by economic headwinds and currency fluctuations, despite strategic efforts including the acquisition of Hiya Health Products.

USANA Health Sciences reported a decrease in net sales and earnings for 2023, while outlining its strategic focus on increasing active customers and expanding into new markets.

Peter Benedict, CHIEF INFORMATION OFFICER of Usana Health Sciences Inc, reported multiple transactions in common stock on July 25, 2026.

Kathryn Michelle Armstrong, CHIEF SCIENTIFIC OFFICER of Usana Health Sciences Inc, reported multiple transactions in common stock on July 25, 2026.

Timothy E Wood, a Director of Usana Health Sciences Inc, reported multiple transactions in common stock on July 23, 2026.

Frederic J Winssinger, a Director of Usana Health Sciences Inc, reported multiple transactions in common stock on July 23, 2026.

J Scott Nixon, a Director of Usana Health Sciences Inc, reported multiple transactions in common stock on July 23, 2026.

Gilbert A Fuller, a Director of Usana Health Sciences Inc, reported multiple transactions in common stock on July 23, 2026.

USANA Health Sciences announces its 2026 Annual Meeting of Shareholders, to be held virtually on May 20, 2026, with key proposals including director elections and executive compensation.

USANA Health Sciences is asking shareholders to approve the USANA Health Sciences, Inc. 2025 Equity Incentive Plan to continue providing equity awards to directors, executive officers, employees, and consultants.

USANA Health Sciences is soliciting proxies for its upcoming Annual Meeting of Shareholders, featuring proposals including the election of directors, approval of the 2025 Equity Incentive Plan, and ratification of KPMG as the independent auditor.

USANA Health Sciences will hold its annual shareholder meeting virtually on May 19, 2025, to vote on key proposals including the election of directors, approval of the 2025 Equity Incentive Plan, ratification of KPMG LLP as the independent auditor, and executive compensation.

USANA Health Sciences announces its 2025 Annual Meeting of Shareholders to be held virtually on May 19, 2025, with key proposals including director elections, approval of a new equity incentive plan, and ratification of the independent auditor.

USANA Health Sciences, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Dr. Myron W. Wentz and Gull Global Limited affirm their 40.1% beneficial ownership in USANA Health Sciences, Inc., primarily for investment purposes, while reserving rights for future strategic actions.

The Vanguard Group has reported a complete divestment of its beneficial ownership in USANA Health Sciences Inc. following an internal corporate realignment.

Dimensional Fund Advisors LP has filed an amended Schedule 13G, disclosing a 4.6% beneficial ownership stake in USANA Health Sciences Inc. as of December 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.4% beneficial ownership stake in USANA Health Sciences Inc. common stock as of December 31, 2025.

Pzena Investment Management, LLC has reported a 6.6% beneficial ownership stake in USANA Health Sciences Inc. common stock.

Dimensional Fund Advisors LP has reported a passive 5.0% beneficial ownership stake in USANA Health Sciences Inc. common stock.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 5.43% in USANA Health Sciences Inc.'s common stock.